EAU 2020: Active Surveillance Proves Safe and Noninferior to Primary Intervention for Small Renal Masses
J.G. Cheaib, MD, MPH, and P.M. Pierorazio, MD, of the Johns Hopkins University School of Medicine, Baltimore, Maryland, and colleagues sought to describe 10-year outcomes in patients with small renal masses.
Published in Urology
News · July 17, 2020
July 17, 2020—Arnheim, The Netherlands—Active surveillance appears to be as safe as and not inferior to primary intervention in carefully selected patients with small renal masses suspected of being renal cell carcinoma.
Small renal masses were defined as solid renal masses ≤4.0 cm (clinical stage T1a).
This conclusion, based on results of an analysis of a prospective, comparative study from the large, multi-institutional Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) registry, which captures 10 years of experience thus far, was reported as part of the virtual 35th Annual Congress of the European Association of Urology (EAU).